28.87USD-2.40%Mkt Cap: 1.67B USDP/E: —Last update: 2026-05-22
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Company
Market Cap1.67B USD
Enterprise Value1.45B USD
Revenue (TTM)—
Gross Profit-92.92M USD
Net Income (TTM)-105.04M USD
Revenue/Share—
Last Price28.87 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees231
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS14070B3096
Valuation
P/E (Trailing)—
P/E (Forward)-38.73
PEG0.38
EV/EBITDA-12.29
EV/Revenue—
P/S—
P/B6.12
EPS (TTM)-2.32
EPS (Forward)-0.76
52W Range
4.30068% of range40.37
52W High40.37 USD
52W Low4.300 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-34.35%
ROA-29.51%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-69.81M USD
CapEx (TTM)11.72M USD
FCF Margin—
FCF Yield-4.22%
Net Debt-263.83M USD
Net Debt/EBITDA2.24
Balance Sheet
Debt/Equity0.05
Current Ratio8.42
Quick Ratio8.28
Book Value/Sh4.833 USD
Cash/Share4.811 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateJun 5, 2019
Splits
Last Split1:10
Split DateJun 5, 2019
Analyst Consensus
Rating1.2 (Strong Buy)
Target (Mean)54.11 USD
Target Range38.00 USD – 63.00 USD
# Analysts9
Ownership
Shares Out.57.91M
Float48.55M
Insiders9.47%
Institutions59.77%
Short Interest
Short Ratio10.7d
Short % Float20.08%
Short % Out.18.18%
Shares Short10.52M
Short (prev mo.)9.88M
Technical
SMA 5031.75 (-9.1%)
SMA 20019.47 (+48.3%)
Beta0.48
S&P 52W Chg28.31%
Avg Vol (30d)1.09M
Avg Vol (10d)1.40M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—